MVZ GynKrefeld GmbH — Clinical Trial Site

8 Registered trials

5 Currently recruiting

Organisation

MVZ GynKrefeld GmbH

Location

Krefeld, Germany

Identifier

ORG-100049445

Address

Lutherplatz 40, Diessem/Lehmheide, 47805, Germany

Departments

Gynäkologischen Krebszentrums
MVZ GynKrefeld GmbH
N/A
Obstetrics & Gynecologic Oncology
Onco-Gynaecology
Onco-Gynecology
ZAGO Zentrum für ambulante gyn. Onkologie
Zentrum für ambulante gynäkologische Onkologie (ZAGO) - MVZ GynKrefeld GmbH

Clinical trials at this site (8)

Search interface

A Study to compare RLY-2608 + Fulvestrant with Capivasertib + Fulvestrant in people with PIK3CA-mutated, hormone-receptor positive, HER2-neg… Recruiting

2025-523083-21-00 PIK3CA-mutant Hormone Receptor Positive, Human Epiderma 5 2025-12-08
Pembrolizumab in combination with lenvatinib in patients with recurrent, persistent, metastatic or locally advanced vulvar cancer not amenab… Recruiting

2024-515646-16-00 Recurrent, persistent, metastatic or locally advanced v 4 2025-06-24
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer … Recruiting

2024-512279-10-00 Triple Negative Breast Cancer 5 2024-11-25
STUDY OF OP-1250 ADMINSTERED AS MONOTHERAPY AND COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2– ADVANCED OR METASTATIC BREAST C… Recruiting

2023-505871-63-00 ER+, HER2- metastatic breast cancer following endocrine 5 2024-04-08
A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF)… Recruiting

2023-504323-25-01 breast cancer 5 2024-03-19
A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα) high recurrent ovarian cancer eligible fo… Ended

2024-516959-40-00 This trial evaluates the efficacy and safety of Mirvetu 4 2021-08-17
A randomized, controlled, open-label, phase III-trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combi… Ended

2023-509242-35-00 HR+/HER2- early breast cancer 5 2020-07-23
A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negati… Ended

2023-508472-11-00 Patients with early breast cancer 5 2018-06-13